Skip to search formSkip to main contentSkip to account menu

TAS 102

Known as: TAS-102, TAS102, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102 
An orally bioavailable combination agent composed of the cytotoxic pyrimidine analog trifluridine (5-trifluoro-2'-deoxythymidine or TFT) and a… 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (4)

Drug CombinationsTrifluridineUraciltipiracil / Trifluridine
NCIt Antineoplastic Agent Terminologyanalogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer.
2019
2019
CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma…
481 Background: D is a human monoclonal antibody (mAb) that inhibits binding of programmed cell death ligand 1 (PD-L1) to its… 
2018
2018
A Pilot Study of Apatinib as Third‐Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer
2017
2017
The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy
2017
2017
Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer under oral trifluridine-tipiracil (TAS-102) chemotherapy.
BACKGROUND/AIM The effect of oral trifluridine-tipiracil (TAS-102)-induced neutropenia on survival of patients with advanced… 
Review
2016
Review
2016
Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer.
BACKGROUND TAS-102 is an anti-metabolite which demonstrated activity against multidrug-resistant advanced colorectal cancer. Its… 
2015
2015
Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups.
646 Background: TAS-102 is comprised of an antineoplastic thymidine-based nucleoside analog, trifluridine, and the thymidine… 
Highly Cited
2004
Highly Cited
2004
An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA.
TAS-102 is a combination drug consisting of alpha,alpha,alpha-trifluorothymidine (FTD) and thymidine phosphorylase inhibitor (TPI… 
Highly Cited
2004
Highly Cited
2004
Synthesis and evaluation of 6-methylene-bridged uracil derivatives. Part 2: optimization of inhibitors of human thymidine phosphorylase and their selectivity with uridine phosphorylase.
2004
2004
Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model.
TAS-102 is a new oral anti-cancer drug preparation, composed of a 1:0.5 mixture (on a molar basis) of alpha,alpha,alpha… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)